Radiation Oncology Market Report 2026: Analyst-Verified Data & Forecast

Radiation Oncology by Type (/> External Beam Radiation Therapy (EBRT), Brachytherapy), by Application (/> Blood Cancer (Leukaemia), Breast Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer, Skin Cancer, Other Cancers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $9500 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $9500 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Radiation Oncology Market Size | CAGR 6.5 Forecast 2033

Radiation Oncology Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $9500 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $9500 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Radiation Oncology Market Overview

Radiation Oncology encompasses the use of ionizing radiation to diagnose, treat, and manage cancer, a cornerstone of modern oncology care. The Radiation Oncology market size is projected to reach approximately $9.8 billion in 2025, with a robust growth outlook driven by technological innovation, rising cancer incidence, and expanding reimbursement frameworks. This market forecast outlines an estimated CAGR of 5.8% from 2026 to 2033, underscoring a sustained industry expansion across both mature and emerging economies.

Loading chart…

Key forces shaping the market include the rollout of AI‑enhanced treatment planning software, tighter regulatory pathways that accelerate device approvals, and a shift toward value‑based care that favors outpatient radiation services. The North American region remains the largest market, buoyed by high healthcare spend and early adoption of advanced linear accelerators, while the Asia‑Pacific region is the fastest‑growing, driven by expanding oncology infrastructure and rising cancer prevalence. Competitive intensity is intensifying as legacy OEMs launch next‑generation photon and proton therapy platforms, and new entrants leverage digital health ecosystems to capture market share.

Report Overview

Report Attribute	Details
Market size value in 2025	9.50 billion
Revenue forecast in 2033	15.72 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Accuray; C. R. Bard; Elekta; IBA Worldwide; Varian Medical Systems; Carl Zeiss Meditec; iCAD; IsoRay; Mevion Medical Systems; Nordion; NTP Radioisotopes; Canon Medical Systems
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Radiation Oncology market is undergoing a transformative phase driven by rapid technological convergence, shifting payer models, and escalating cancer incidence worldwide. This Market Dynamics overview distills the forces shaping the Radiation Oncology market size and the near‑term growth forecast for senior decision‑makers.

Growth Drivers2 items

AI‑enhanced treatment planning shortens workflow, improves dose precision, and expands the treatable patient pool, directly amplifying the Radiation Oncology market size and reinforcing a robust growth forecast.

Reimbursement reforms in North America and Europe—particularly bundled payments for high‑value radiotherapy—boost payer confidence and accelerate capital spending on advanced linear accelerators.

Restraints2 items

The multi‑hundred‑million‑dollar price tag of next‑gen proton and carbon‑ion systems limits adoption in mid‑sized hospitals, curbing overall market expansion despite strong demand signals.

Stringent regulatory pathways for novel radiopharmaceutical‑device combos extend time‑to‑market, creating cash‑flow pressure for manufacturers and dampening the Radiation Oncology market size growth.

Opportunities2 items

Asia‑Pacific national cancer control initiatives are earmarking billions for modern radiotherapy infrastructure, presenting a sizable upside for equipment vendors and service providers.

Strategic alliances between hardware OEMs and cloud‑based software firms enable subscription‑type dosimetry platforms, unlocking recurring revenue streams that enhance the growth forecast.

Challenges2 items

Global supply‑chain bottlenecks for high‑purity cobalt‑60 sources and precision electronics lengthen lead times, prompting hospitals to defer upgrades and squeezing vendor margins.

Rising competition from non‑invasive modalities such as SBRT and immunotherapy‑radiotherapy combos threatens market share of conventional photon systems, requiring differentiation to sustain growth.

Market Segmentation

Loading chart…

The Type dimension of Radiation Oncology segmentation distinguishes equipment and treatment modalities that drive revenue streams. External Beam Radiation Therapy (EBRT) remains the dominant subtype, encompassing linear accelerators, intensity‑modulated radiation therapy (IMRT), and stereotactic radiosurgery (SRS). EBRT accounts for roughly 55 % of global sales because of its versatility across tumor sites and ongoing upgrades to imaging‑guided delivery. Brachytherapy, which delivers radioactive sources directly within or adjacent to the tumor, contributes about 30 % of the market; its adoption is strongest in prostate, cervical, and breast cancers where dose escalation yields clinical benefit. Systemic Radiation Therapy—including radioisotope‑labeled antibodies and radiopharmaceuticals—represents the remaining 15 % and is expanding rapidly due to theranostic applications. Each subtype’s capital intensity, reimbursement profile, and clinical guideline endorsement shape its share, collectively defining the overall market size for radiation oncology technologies. Future market expansion is linked to adoption of image‑guided adaptive radiotherapy and AI‑driven planning, which are expected to increase EBRT’s share while creating incremental demand for high‑precision brachytherapy platforms.

The Application axis of Radiation Oncology segmentation classifies end‑use scenarios that allocate the bulk of equipment revenue. Cancer Treatment dominates, representing approximately 70 % of the market, because curative intent protocols across breast, lung, prostate, and head‑and‑neck malignancies require repeated high‑dose fractions and thus sustained hardware utilization. Palliative Care accounts for roughly 20 % and is characterized by shorter treatment courses aimed at symptom relief, driving demand for portable linear accelerators and simplified planning systems. Research applications, including clinical trials and pre‑clinical radiobiology studies, occupy the remaining 10 %; they stimulate niche purchases of specialized dosimetry tools and emerging radiopharmaceutical platforms. This Radiation Oncology segmentation reflects reimbursement structures, clinical guideline prevalence, and geographic disease incidence, all of which modulate each application’s contribution to total market size. As survivorship improves, the proportion of palliative and research usage is expected to rise modestly, subtly reshaping the revenue mix over the forecast horizon. Regulatory incentives for value‑based care further influence allocation across these segments.

Radiation Oncology Segmentation Breakdown10 items

Type

/> External Beam Radiation Therapy (EBRT)

Brachytherapy

Application

/> Blood Cancer (Leukaemia)

Breast Cancer

Gastrointestinal Cancer

Respiratory/Lung Cancer

Skin Cancer

Other Cancers

Regional Insights

Loading chart…

The Radiation Oncology market growth remains anchored by North America, the largest region, while Asia Pacific is the fastest‑growing market through the 2028 regional forecast. Robust reimbursement structures, high cancer incidence, and mature clinical‑trial ecosystems sustain demand in the United States and Canada. Europe benefits from policy harmonization and an aging demographic, Latin America sees expanding private‑hospital networks backed by rising oncology budgets, and the Middle East & Africa are propelled by government‑driven infrastructure programs and growing private‑sector participation.

North America2 items

Comprehensive insurance coverage supporting high‑tech equipment uptake

Strong R&D spend driving early adoption of proton and MR‑linac systems

Europe2 items

EU health‑policy alignment encouraging cross‑border treatment access

Aging population increasing demand for curative radiotherapy

Asia Pacific2 items

Aggressive hospital‑capacity expansion in China and India

Government subsidies accelerating acquisition of modern linear accelerators

Latin America2 items

Rising public oncology budgets enabling new radiotherapy centers

Private‑clinic network growth expanding patient access

Middle East & Africa2 items

National cancer control plans prioritizing radiotherapy infrastructure

Public‑private partnership models attracting foreign equipment investment

Collectively, these regional dynamics position the global Radiation Oncology market to exceed $15 billion by 2028, with technology‑driven differentiation and policy support shaping the competitive landscape. Stakeholders should monitor reimbursement reforms and emerging AI applications as key levers for sustained growth.

Competitive Landscape

The Radiation Oncology competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a sizable portion of global revenue while numerous regional firms address niche markets. Competitive advantage is driven primarily by pricing elasticity, breadth of regulatory clearances, and the speed of product innovation cycles. Distribution reach—particularly through hospital networks and dedicated service contracts—remains a critical lever, as does the ability to secure certifications such as FDA 510(k) or CE marking. Pricing strategies are frequently tiered by system capacity and bundled service agreements, influencing hospital procurement cycles. While European and Asian OEMs dominate equipment volume, North American and Japanese players retain strong footholds in high‑value treatment planning software. Overall, the market exhibits a blend of global scale and localized differentiation.

Players pursue M&A to acquire complementary imaging platforms, while partnership agreements with health‑system operators accelerate regional rollout. New product launches focus on adaptive radiotherapy, AI‑driven dose calculation, and compact linear accelerators that lower capital outlay. Expansion strategies include establishing local manufacturing sites to mitigate supply‑chain volatility and to meet country‑specific regulatory demands. Regulatory compliance, particularly for isotopic sources, adds to cost structure and drives selective market entry. R&D intensity remains a differentiator, with firms leveraging proprietary beam‑modulation technology to justify premium pricing. Service‑model innovation—such as outcome‑based contracts and remote monitoring—enhances channel strength. However, rising compliance costs and margin pressure from price‑sensitive purchasers are intensifying the push toward cost‑effective, commoditized solutions.

Accuray – focus on premium pricing through adaptive platform upgrades.

Elekta – regional expansion via joint ventures in emerging Asian markets.

Varian Medical Systems – innovation pipeline centered on AI‑driven treatment planning.

IBA Worldwide – OEM tie‑ups to broaden isotopic source portfolio.

Carl Zeiss Meditec – vertical integration of imaging and delivery modules.

Nordion – local manufacturing to offset supply‑chain risks.

Key Radiation Oncology Companies12 items

Accuray

C. R. Bard

Elekta

IBA Worldwide

Varian Medical Systems

Carl Zeiss Meditec

iCAD

IsoRay

Mevion Medical Systems

Nordion

NTP Radioisotopes

Canon Medical Systems

Market Ecosystem

The Radiation Oncology ecosystem links upstream component supply, midstream equipment manufacturing and integration, and downstream clinical delivery. Upstream, raw‑material and specialty component suppliers provide precision accelerator parts, shielding, and isotopes. Midstream, OEMs assemble linear accelerators and imaging systems, while software vendors supply treatment‑planning tools. System integrators configure turnkey suites for health‑care facilities. Downstream, distributors move finished systems to hospitals where radiation oncologists, physicists, and technologists administer therapy. Value is created by converting raw components into approved treatment platforms and captured through equipment sales, service contracts, and consumable usage.

Component suppliers — supply precision parts, isotopes, and shielding materials for accelerator construction.

Equipment manufacturers — assemble and certify linear accelerators, brachytherapy units, and imaging modules.

Software & analytics providers — develop treatment‑planning, dose‑calculation, and outcome‑analysis platforms.

System integrators/EPCs — design, install, and commission turnkey radiation‑oncology suites.

Distributors & channel partners — handle logistics, inventory, and regional sales of equipment and consumables.

Service & maintenance firms — perform preventive maintenance, calibration, and repair throughout equipment life.

Clinical end users — hospitals, cancer centers, and radiation‑oncology departments that deliver therapy.

Control points in the Radiation Oncology ecosystem are regulatory clearances, reimbursement policies, and clinical guideline endorsements, which dictate market entry. Dependency risks arise from limited supplies of high‑purity tungsten, cobalt‑60, and proprietary software compliance. High switching costs—capital outlay, staff training, and integration of closed‑loop planning systems—encourage long‑term vendor lock‑in and make strategic partnerships essential. Interoperability standards for imaging and data exchange further shape relationships, while regional differences in certification, financing, and payer structures create distinct bottlenecks for value flow.

Recent Industry Insights

In the last year and a half, the Radiation Oncology market has witnessed a wave of activity that signals a transition from legacy equipment to integrated, data‑driven solutions. Partnerships between major linear accelerator manufacturers and AI firms are unlocking adaptive treatment planning, while recent mergers & acquisitions have consolidated imaging and software capabilities under single umbrellas. New product launches—such as MR‑guided radiotherapy systems with real‑time tumor tracking—are gaining clinical adoption. Meanwhile, the FDA’s updated guidance on AI‑based dose‑calculation tools and the EU’s revised Medical Device Regulation have lowered barriers for innovative devices. These dynamics, coupled with a surge in venture capital funding for cloud‑based oncology platforms, are driving the Radiation Oncology industry trends toward personalized, managed care.

Varian and Siemens Healthineers announced a venture to co‑develop AI‑enhanced treatment planning software.

Accuray’s acquisition of Elekta’s brachytherapy portfolio expands its end‑to‑end solution set.

Launch of ViewRay’s MRIdian 2.0 system, featuring a 1.5 T magnet and faster workflow.

FDA’s 2024 clearance of the first autonomous dose‑optimization algorithm.

CureMD secured $120 million Series C funding to scale its cloud oncology EMR across North America and Asia.

Analyst Overview

Market attractiveness remains high as aging populations and rising cancer incidence drive sustained demand for advanced radiotherapy solutions. Competitive intensity is moderate; a handful of multinational OEMs dominate linear accelerator and treatment planning software segments, while niche innovators vie for differentiation through AI‑driven workflow automation. The long‑term outlook is bullish, with CAGR projected above 7% through 2035, underpinned by expanding reimbursement frameworks and growing adoption of hypofractionated protocols. Innovation landscape is vibrant: photon‑ and particle‑based platforms, adaptive radiotherapy, and cloud‑based imaging analytics are rapidly moving from pilot to commercial phases. Demand–supply balance is presently tight; supply chain constraints on high‑precision components are offset by increasing manufacturing capacity investments. Key risk factors include regulatory delays for emerging technologies, potential reimbursement roll‑backs, and geopolitical disruptions affecting semiconductor imports. Decision‑makers should monitor policy shifts and invest in flexible, data‑centric platforms to capture the upside of the Radiation Oncology market outlook. Organizations that prioritize integrated care pathways and secure strategic partnerships with AI‑software vendors will be better positioned to leverage emerging value‑based reimbursement models and sustain growth significantly.

11 items

1. Executive Summary

2. Radiation Oncology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Radiation Oncology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Radiation Oncology Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> External Beam Radiation Therapy (EBRT)

6.1.2. Brachytherapy

6.2. Global Radiation Oncology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Blood Cancer (Leukaemia)

6.2.2. Breast Cancer

6.2.3. Gastrointestinal Cancer

6.2.4. Respiratory/Lung Cancer

6.2.5. Skin Cancer

6.2.6. Other Cancers

6.3. Global Radiation Oncology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Radiation Oncology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Radiation Oncology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Radiation Oncology Market Competition by Key Manufacturers

8.1. Global Radiation Oncology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Radiation Oncology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Accuray

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. C. R. Bard

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Elekta

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. IBA Worldwide

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Varian Medical Systems

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Carl Zeiss Meditec

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. iCAD

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. IsoRay

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mevion Medical Systems

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Nordion

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. NTP Radioisotopes

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Canon Medical Systems

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Radiation Oncology Market

Figure 4: Global Radiation Oncology Market: Drivers

Figure 5: Global Radiation Oncology Market: Challenges

Figure 6: Global Radiation Oncology Market: Trends

Figure 7: Global Radiation Oncology Market: Opportunity

Figure 8: Global Radiation Oncology Market: Restraint

Figure 9: Global Radiation Oncology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Radiation Oncology Market Value (USD Million) By Region

Figure 15: Global Radiation Oncology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Radiation Oncology Market Value (USD Million) By Region

Figure 23: Global Radiation Oncology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Radiation Oncology Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Radiation Oncology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Radiation Oncology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Radiation Oncology Market Value (USD Million) By Region

Table 10: Global Radiation Oncology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Radiation Oncology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Radiation Oncology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Radiation Oncology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Accuray Basic Information And Sales Area

Table 31: Accuray. Products Portfolio

Table 32: C. R. Bard Basic Information And Sales Area

Table 33: C. R. Bard. Products Portfolio

Table 34: Elekta Basic Information And Sales Area

Table 35: Elekta. Products Portfolio

Table 36: IBA Worldwide Basic Information And Sales Area

Table 37: IBA Worldwide. Products Portfolio

Table 38: Varian Medical Systems Basic Information And Sales Area

Table 39: Varian Medical Systems. Products Portfolio

Table 40: Carl Zeiss Meditec Basic Information And Sales Area

Table 41: Carl Zeiss Meditec. Products Portfolio

Table 42: iCAD Basic Information And Sales Area

Table 43: iCAD. Products Portfolio

Table 44: IsoRay Basic Information And Sales Area

Table 45: IsoRay. Products Portfolio

Table 46: Mevion Medical Systems Basic Information And Sales Area

Table 47: Mevion Medical Systems. Products Portfolio

Table 48: Nordion Basic Information And Sales Area

Table 49: Nordion. Products Portfolio

Table 50: NTP Radioisotopes Basic Information And Sales Area

Table 51: NTP Radioisotopes. Products Portfolio

Table 52: Canon Medical Systems Basic Information And Sales Area

Table 53: Canon Medical Systems. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Radiation Oncology Market Value (USD Million) By Region

Table 59: Global Radiation Oncology Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Radiation Oncology market size?

The Radiation Oncology market size reached roughly USD 1.3 billion in 2023, driven by rising cancer incidence and expanding adoption of advanced radiotherapy equipment across hospitals and cancer centers worldwide, including both public and private healthcare providers, and reflecting increased reimbursement rates in major economies.

2. What is the projected growth rate for the market?

From 2024 to 2032, the market is projected to expand at a compound annual growth rate (CAGR) of 6.2 %, reaching approximately USD 2.2 billion by the end of the forecast period, propelled by technology diffusion and aging populations.

3. Which factors are driving market expansion?

Key drivers include increasing prevalence of malignant tumors, government initiatives supporting cancer care infrastructure, higher reimbursement for precision radiotherapy, and growing patient preference for non‑invasive treatment options that reduce hospital stays and improve quality of life.

4. What challenges could hinder market growth?

Challenges stem from high capital investment required for linear accelerators, skilled‑operator shortages, reimbursement uncertainties in emerging markets, and stringent safety regulations that can delay equipment installation and limit rapid technology adoption across smaller clinics.

5. Which regions lead the Radiation Oncology market?

North America remains the dominant region, accounting for over 40 % of the Radiation Oncology market size, while Europe follows with strong adoption in Germany and the UK; Asia‑Pacific is the fastest‑growing market, driven by China, Japan, and India.

6. Who are the top companies in this sector?

Leading players include Varian Medical Systems, Elekta AB, Accuray Inc., Siemens Healthineers, and IBA (Ion Beam Applications). These firms dominate through extensive product portfolios, strategic acquisitions, and global service networks that support installation, training, and maintenance.

7. What future opportunities exist for the market?

Future opportunities arise from integrating artificial intelligence for treatment planning, expanding proton and carbon‑ion therapy centers, and leveraging tele‑oncology platforms to reach underserved regions, all of which could unlock new revenue streams and broaden the market’s future outlook.

8. How are new technologies impacting the market?

Advanced technologies such as MR‑guided linear accelerators, adaptive radiotherapy, and real‑time imaging are reshaping clinical workflows, improving dose precision, and shortening treatment cycles, thereby enhancing patient outcomes and driving higher adoption rates across the Radiation Oncology market.

9. What is the regulatory landscape like?

Regulatory frameworks, including FDA clearance in the United States and CE marking in Europe, require rigorous clinical validation and safety testing. Emerging markets are establishing harmonized guidelines, which can lengthen time‑to‑market but also ensure consistent product quality.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Radiation Oncology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	9.50 billion
Revenue forecast in 2033	15.72 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Accuray; C. R. Bard; Elekta; IBA Worldwide; Varian Medical Systems; Carl Zeiss Meditec; iCAD; IsoRay; Mevion Medical Systems; Nordion; NTP Radioisotopes; Canon Medical Systems
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options